Attached files
| file | filename |
|---|---|
| 10-K - 10-K - MERRIMACK PHARMACEUTICALS INC | mack-10k_20191231.htm |
| EX-32.2 - EX-32.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex322_10.htm |
| EX-32.1 - EX-32.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex321_9.htm |
| EX-31.2 - EX-31.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex312_11.htm |
| EX-31.1 - EX-31.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex311_6.htm |
| EX-23.2 - EX-23.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex232_188.htm |
| EX-21.1 - EX-21.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex211_7.htm |
| EX-4.5 - EX-4.5 - MERRIMACK PHARMACEUTICALS INC | mack-ex45_189.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-222093) and Form S-8 (Nos. 333-180996, 333-186370, 333-194313, 333-202346, 333-209745, 333-223577 and 333-230084) of Merrimack Pharmaceuticals, Inc. of our report dated March 6, 2019 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 12, 2020